Abstract 73P
Background
The number of typical and atypical (defined as mitoses with any morphological appearance other than the typical forms) mitotic figures (MFs) and a high atypical-to-typical mitosis ratio are strongly associated with tumour aggressivity, survival rates, and a predictor of poor response to chemotherapy in breast cancer. Manual detection is time consuming, especially on whole slide images (WSIs). An automated approach is therefore necessary to investigate these aspects on a larger scale. We demonstrate that deep learning can be used to automate this detection, improving on the performance of pathologists.
Methods
All MFs in the mammary carcinoma dataset (21 hematoxylin and eosin (H&E)-stained WSIs with ∼14 000 MFs and ∼36 000 hard negatives) were labelled as typical or atypical. These slides (originally scanned on a Leica scanner) were then rescanned on six other scanners (2x Hammamatsu, 2x 3DHISTECH, Philips, Olympus), and the annotations were registered. This gave a large, multi-scanner dataset, which was used to train a YOLOv6 deep learning object detection model. For testing, all MFs in the (human) TUPAC16 and MIDOG21 datasets were labelled by two pathologists as either typical or atypical. In cases of disagreement, a third reader gave a consensus. We used the alternative version of the TUPAC16 dataset provided by the same authors as the MIDOG21 dataset to reduce potential label bias. We then ran our model on these images and compared the mean average precision (mAP) vs the consensus to the mAPs of the two individual pathologists vs the consensus.
Results
The mAP of our model (0.80) was higher than the average mAP of the two pathologists (0.75, p<0.05), showing that the model can successfully automate the process of MF detection. There was considerable disagreement in the labelling by the two pathologists (14% of cases). By automating the process we reduce this variability, meaning we can more consistently predict clinical outcomes (e.g. survival rates) from our results.
Conclusions
The numbers of both typical and atypical MFs are indicators of patient survival and response to treatment. We have demonstrated an automated deep learning model that can accurately detect these figures and could thus be used for patient survival prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tribun.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
13P - Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates
Presenter: Anna-Maria Georgoudaki
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - Lentivirally overexpressed c-Myc promoter binding protein (MBP-1) localizes in the cytoplasm of human cutaneous melanoma cell lines increasing cell proliferation and glycolysis rate
Presenter: Miriam Hippner-Kunicka
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments
Presenter: Mario Kuttke
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells
Presenter: Luiz Gustavo Chuffa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
Presenter: Marina Rodriguez-Candela Mateos
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
Presenter: Vlada Zakharova
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Presenter: Pranshu Sahgal
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Cross-resistance between platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi) in castration-resistant prostate cancer (CRPC)
Presenter: Peter Slootbeek
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer
Presenter: Deniz Gulfem Ozturk
Session: Cocktail & Poster Display session
Resources:
Abstract